Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

ABSTRACT:

Purpose

Residual disease following primary cytoreduction is associated with adverse overall survival in patients with epithelial ovarian cancer. Accurate identification of patients at high risk of residual disease has been elusive, lacking external validity and prompting many to undergo unnecessary surgical exploration. Our goal was to identify and validate molecular markers associated with high rates of residual disease.

Methods

We interrogated two publicly available datasets from chemonaïve primary high-grade serous ovarian tumors for genes overexpressed in patients with residual disease and significant at a 10% false discovery rate (FDR) in both datasets. We selected genes with wide dynamic range for validation in an independent cohort using quantitative RT-PCR to assay g

SUBMITTER: Tucker SL 

PROVIDER: S-EPMC4062703 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature